Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs

Arthritis Care and Research

Volumn 64, Issue 12, 2012, Pages 1903-1909

  Taroumian, Sara ^a,b   Knowles, Susan L ^a   Lisse, Jeffrey R ^a   Yanes, James ^a   Ampel, Neil M ^a   Vaz, Austin ^c   Galgiani, John N ^a   Hoover, Susan E ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Catalina Pointe Rheumatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL RESPONSE MODIFIER; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FLUCONAZOLE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL ARTICLE; COCCIDIOIDOMYCOSIS; DRUG WITHDRAWAL; ENTERITIS; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL RECORD REVIEW; MONOTHERAPY; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SPONDYLITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ANTIRHEUMATIC AGENTS; COCCIDIOIDOMYCOSIS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC FACTORS; MIDDLE AGED; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; YOUNG ADULT;

EID: 84870530971     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21784     Document Type: Article

References (15)

1. Hector RF, Rutherford GW, Tsang CA, Erhart LM, McCotter O, Anderson SM, et al. The public health impact of coccidioidomycosis in Arizona and California. Int J Environ Res Public Health 2011; 8: 1150-73.
2. Valdivia L, Nix D, Wright M, Lindberg E, Fagan T, Lieberman D, et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg Infect Dis 2006; 12: 958-62.
3. Kim MM, Blair JE, Carey EJ, Wu Q, Smilack JD,. Coccidioidal pneumonia, Phoenix, Arizona, USA, 2000-2004. Emerg Infect Dis 2009; 15: 397-401.
4. Hector RF, Laniado-Laborin R,. Coccidioidomycosis: a fungal disease of the Americas. PLoS Med 2005; 2: e2.
5. Blair JE, Logan JL,. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis 2001; 33: 1536-44.
6. Giles JT, Bathon JM,. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004; 19: 320-34.
7. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
8. Mertz LE, Blair JE,. Coccidioidomycosis in rheumatology patients: incidence and potential risk factors. Ann N Y Acad Sci 2007; 1111: 343-57.
9. Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. Arthritis Rheum 2004; 50: 1959-66.
10. Pappagianis D, Zimmer BL,. Serology of coccidioidomycosis. Clin Microbiol Rev 1990; 3: 247-68.
11. Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA, et al. Coccidioidomycosis. Clin Infect Dis 2005; 41: 1217-23.
12. Johnson WM, Gall EP,. Fatal coccidioidomycosis in collagen vascular diseases. J Rheumatol 1983; 10: 79-84.
13. Ampel NM, Ryan KJ, Carry PJ, Wieden MA, Schifman RB,. Fungemia due to Coccidioides immitis: an analysis of 16 episodes in 15 patients and a review of the literature. Medicine (Baltimore) 1986; 65: 312-21.
14. Ampel NM,. The complex immunology of human coccidioidomycosis. Ann N Y Acad Sci 2007; 1111: 245-58.
15. Ampel NM, Kramer LA, Li L, Carroll DS, Kerekes KM, Johnson SM, et al. In vitro whole-blood analysis of cellular immunity in patients with active coccidioidomycosis by using the antigen preparation T27K. Clin Diagn Lab Immunol 2002; 9: 1039-43.